Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn on November 16, 2020. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations by total revenue. Viatris announced a cost-reducing restructuring plan which would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world. The company reported in the first quarter of 2021 USD 4.4M in earnings, which is up 70% year over year, with a gross profit margin of 59.6%, up from 52.7% in the same period in 2020. The company is well suited to add biosimilars and complex generics to its arsenal, driving up revenue. It already has 1,400 approved molecules across a range of therapies, and it has recently come up with several new ones. In March 2021, it got tentative approval from the Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA) for a generic version of Symbicort, which is indicated for patients with asthma or chronic obstructive pulmonary disease. The drug brought in USD 2.7B in revenue last year for AstraZeneca.
Viatris Inc (VTRS)
Stay updated with Viatris Inc (VTRS) share price insights, trends, and market data. Make informed trading decisions with FP Markets Hong Kong.